Hervycta Plus 440mg Injection

About

Trastuzumab is a highly effective monoclonal antibody specifically engineered to target the human epidermal growth factor receptor 2 (HER2) protein. This protein is frequently overexpressed on the surface of certain aggressive cancer cells, notably in HER2-positive breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. By selectively binding to the HER2 receptor, trastuzumab effectively blocks the signaling pathways that promote cell growth and division, thereby inhibiting the proliferation of these malignant cells and ultimately leading to their destruction. It represents a critical component of modern oncology, significantly improving patient prognosis and extending survival rates when administered as a monotherapy or in conjunction with various chemotherapy regimens. This targeted therapeutic approach not only helps to reduce tumor burden and prevent disease progression but also offers a more precise treatment strategy for patients whose tumors exhibit HER2 overexpression.

Uses

• Treatment of HER2-positive early breast cancer.
• Treatment of HER2-positive metastatic breast cancer.
• Treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
• Adjuvant therapy after surgery, chemotherapy, and radiation for early breast cancer.

Directions For Use

This medication is administered as an intravenous infusion by a qualified healthcare professional. The dosage and frequency will be determined by your doctor based on your condition.

Benefits

• Targets HER2-positive cancer cells specifically.
• Significantly improves progression-free and overall survival.
• Reduces the risk of cancer recurrence in early stages.
• Can be used in combination with chemotherapy for enhanced efficacy.
• Offers a targeted approach with potentially fewer systemic side effects than traditional chemotherapy alone.
• Effective in both early and metastatic disease settings.

Side Effects

• Infusion-related reactions (fever, chills, nausea)
• Cardiomyopathy (heart muscle weakness)
• Diarrhea
• Nausea and vomiting
• Headache
• Fatigue
• Rash
• Anemia
• Neutropenia (low white blood cell count)
• Muscle pain
• Abdominal pain
• Cough

Safety Measures

• Alcohol - Alcohol consumption should be discussed with your doctor, as it may exacerbate certain side effects or interact with concurrent medications.
• Pregnancy - Trastuzumab is not recommended during pregnancy due to potential harm to the fetus. Effective contraception should be used during treatment and for 7 months after the last dose.
• Breastfeeding - Breastfeeding is generally not advised during treatment with trastuzumab and for 7 months after the last dose, as it may pass into breast milk.
• Liver - Use with caution in patients with pre-existing liver conditions. Liver function should be monitored regularly during treatment.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution and monitoring are advised in severe cases.
• Lung - Patients with pre-existing lung conditions or a history of pulmonary toxicity should be monitored closely due to the risk of interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.